These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 37543834)
1. Efficacy of ranibizumab combined with photocoagulation for diabetic retinopathy: A meta-analysis study. Yin H; Zhong S Medicine (Baltimore); 2023 Aug; 102(31):e34170. PubMed ID: 37543834 [TBL] [Abstract][Full Text] [Related]
2. ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy. Barroso RMP; Messias K; Garcia DM; Cardillo JA; Scott IU; Messias A; Jorge R Arq Bras Oftalmol; 2020; 83(6):526-534. PubMed ID: 33470281 [TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Virgili G; Parravano M; Menchini F; Brunetti M Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642 [TBL] [Abstract][Full Text] [Related]
5. Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation. Cao G; Xu X; Wang C; Zhang S Eur J Ophthalmol; 2020 Jan; 30(1):34-39. PubMed ID: 30539668 [TBL] [Abstract][Full Text] [Related]
6. Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis. Xie X; Lian C; Zhang Z; Feng M; Wang W; Yuan X; Shi Y; Liu T Front Endocrinol (Lausanne); 2023; 14():1144422. PubMed ID: 37260449 [TBL] [Abstract][Full Text] [Related]
15. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity. Chang E; Josan AS; Purohit R; Patel CK; Xue K Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study. Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies. Xiao K; Li FZ; Liang SZ; Wang J; Qian C; Wan GM Ann Pharmacother; 2020 Aug; 54(8):750-756. PubMed ID: 32005079 [No Abstract] [Full Text] [Related]
18. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. Krick TW; Bressler NM Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal steroids for macular edema in diabetes. Rittiphairoj T; Mir TA; Li T; Virgili G Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392 [TBL] [Abstract][Full Text] [Related]
20. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC; Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]